Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 106, Issue 5, Pages 1133-1140Publisher
WILEY
DOI: 10.1002/cpt.1555
Keywords
-
Categories
Funding
- Sandler Family Foundation
- American Asthma Foundation
- RWJF Amos Medical Faculty Development Program
- Harry Wm. and Diana V. Hind Distinguished Professor in Pharmaceutical Sciences II, National Institutes of Health [R01HL117004, R01HL128439, R01HL135156, 1X01HL134589, R01HL141992]
- National Institute of Environmental Health Sciences [R01ES015794, R21ES24844]
- National Institute on Minority Health and Health Disparities [P60MD006902, R01MD010443]
- National Institute of General Medical Sciences [RL5GM118984]
- Tobacco-Related Disease Research Program [24RT-0025, 27IR-0030]
- Ramon y Cajal Program [RYC-2015-17205]
- Spanish Ministry of Economy, Industry and Competitiveness (MINECO/AEI/FEDER, UE) [SAF2017-83417R]
- Insituto de Salud Carlos III through Strategic Action for Health Research (AES) [AC15/00015]
- European Community (EC) within the Active and Assisted Living (AAL) Programme framework
- SysPharmPedia grant from the ERACoSysMed 1st Joint Transnational Call from the European Union under the Horizon 2020
- National Institute of General Medical Sciences of the National Institutes of Health [5T32GM007546-42]
Ask authors/readers for more resources
American Thoracic Society guidelines recommend inhaled corticosteroid (ICS) therapy, plus a short-acting bronchodilator, in patients with persistent asthma. However, few prior studies have examined the efficacy of this combination in children of all racial/ethnic groups. We evaluated the association between ICS use and bronchodilator response (BDR) in three pediatric populations with persistent asthma (656 African American, 916 Puerto Rican, and 398 Mexican American children). The association was assessed using multivariable quantile regression. After adjusting for baseline forced expiratory volume in one second and use of controller medications, ICS use was significantly associated with increased BDR only among Mexican Americans (1.56%, P = 0.028) but not African Americans (0.49%, P = 0.426) or Puerto Ricans (0.16%, P = 0.813). Our results demonstrate that ICS augmentation is disproportionate across racial/ethnic groups, where improved BDR is observed in Mexican Americans only. This study highlights the complexities of treating asthma in children, and reinforces the importance of investigating the influence of race/ethnicity on pharmacological response.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available